Forty percent of LG-ESS patients do not respond to current therapeutic regimens (Amant et al., 2007; Beck et al., 2012), highlighting the need for greater understanding of JAZF1-SUZ12 function. The gene discussed is JAZF1; the disease is endometrioid stromal sarcoma.